Allied Market Research
Loading...
0
New
New
2021
Cancer Immunotherapy Market

Cancer Immunotherapy Market by Technology Type (Monoclonal Antibodies, Cytokines & Immunomodulators, and Others), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others), and End user (Hospitals, Cancer Research Centers, and Clinics): Global Opportunity Analysis and Industry Forecast, 2021-2030

A01913
Pages: 207
Jul 2021 | 15500 Views
   
Author(s) : Kishor Sherkar, Stephy Varghese , Onkar Sumant
Tables: 113
Charts: 53
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Cancer Immunotherapy Market

Request Now !

Cancer Immunotherapy Market Overview 2030:

The global cancer immunotherapy market size was valued at $85,603.50 million in 2020, and is projected to reach $309,667.65 million by 2030, registering a CAGR of 14.1% from 2021 to 2030.

The COVID-19 pandemic has drastically affected buying capacity of hospitals, especially small-scale hospitals and scanning centers. According to an article by Cigna, there has been reductions in hospitalizations for non-elective conditions such as acute coronary syndromes and transient ischemic attacks that raise the possibility that patients may be deferring necessary elements of clinical care. The clinical trials of the new cancer immunotherapy drugs are kept on hold, as during this crisis the individual is more susceptible to suffer from COVID-19. COVID friendly cancer treatment however, are observed to be increased during the course of time and would propel in the coming years. Thus, the COVID-19 pandemic is anticipated to have a negative impact on the cancer immunotherapy market.

Cancer immunotherapy is a cancer treatment that enhances the immune system's ability to fight cancer. This therapy is preferable than the old technique because it provides long-term cancer protection, has less side effects, and treats a wider range of cancer. Cancer immunotherapy is used in different types of cancers such as melanoma, prostate cancer, breast cancer, colorectal cancer, lung cancer, head & neck cancer, and more. Immunotherapy works by directing the immune system toward cancer-specific targets, activating the immune system to mobilize the target, and triggering a response capable of destroying cancer cells. 

Cancer-Immunotherapy-Market-2021-2030

Get more information on this report : Request Sample Pages

There are many factors, such as increase in healthcare expenditure, rise in incidence of cancer, surge in access to medical insurance, and surge in technological advancements in cancer treatment therapies expected to propel the growth of the global cancer immunotherapy market. According to statistics given by national cancer institute in 2020, an estimated 1,806,590 new cases of cancer were diagnosed in the U.S. and 606,520 people passed away due to the disease. This surge in the incidences of cancer propel the growth of the industry in the coming years. Increase in awareness programs regarding the need for cancer immunotherapy is expected to help the market gain traction during the forecast period. However, the factors such as stringent regulations related to cancer immunotherapy are anticipated to hinder the growth of the cancer immunotherapy market. Government have better supervision over the use of immunotherapy and is also taking care of the clinical trials going on user the government norms, which has made it difficult to the companies to enter the industry and is hence expected to hinder the growth of the market. Also, high product developmental cost is anticipated to impede the growth of the cancer immunotherapy market.

Global Cancer Immunotherapy Market Segmentation

The cancer immunotherapy market is categorized into technology type, application, end-user, and region. By technology type, the market is divided into monoclonal antibodies, cytokines & immunomodulators, and others. Monoclonal antibodies held the largest share in 2020, owing to surge in usage of monoclonal antibodies for cancer immunotherapy as they exhibit different properties where immune system can be modulated and hence they can activate or inhibit the molecules targeted on immune system. In addition, monoclonal antibodies also induce the antitumor immune response.

Cancer Immunotherapy Market
By Product

Your browser does not support the canvas element.

The Monoclonal Antibodies segment is expected to lead the market throughout the forecast period.

Get more information on this report : Request Sample Pages

By application, the cancer immunotherapy market is segmented as lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and other applications. The lung cancer market held the largest share in 2020 and is expected to lead the market during the analysis period owing to high incidence of lung cancer worldwide and surge in the awareness program regarding the need for early therapeutics of lung cancer.

Cancer Immunotherapy Market
By Application

Your browser does not support the canvas element.

The lung cancer segment is expected to lead the market throughout the forecast period.

Get more information on this report : Request Sample Pages

On the basis of end user, the market is categorized into hospitals, cancer research centers and clinics. Hospitals held the largest market share of cancer immunotherapy market in 2020, and this segment is projected to show the highest growth rate during the analysis period due to the extensive use of cancer immunotherapy in the hospitals. Furthermore, higher preference toward hospitals is anticipated to boost the growth of the segment during the forecast period. Furthermore, hospitals segment would gain highest CAGR of about 14.7% in the forecast period. 

Cancer Immunotherapy Market
By End User

Your browser does not support the canvas element.

The Hospitals segment spearheaded the market in 2020 and is expected to maintain the dominance throughout the forecast period.

Get more information on this report : Request Sample Pages

Region wise, the cancer immunotherapy market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America was the highest revenue contributor in 2020. This is attributed to the steep rise in amount of expenditure in healthcare, increased focus on maintaining best healthcare system, and increased incidence of cancer worldwide. However, Asia-Pacific is projected to grow with the highest CAGR during the analysis period, owing to rise in healthcare expenditure, surge in per capita income, and improvement in healthcare infrastructure. In addition, Europe is expected to gain second largest revenue share during the forecast period, owing to the development in the infrastructure in the region and rising incidences of cancer.

Cancer Immunotherapy Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

North America held a highest revenue share in 2020, whereas, Europe will be the second-largest value contributor, and Asia-Pacififc is expected to register the fastest CAGR during the forecast period.

Get more information on this report : Request Sample Pages

The key players operating in the global cancer immunotherapy market include Amgen, Inc., Astrazeneca, PLC, Bayer AG, Bristol-Myers Squibb Company, Eli Lily And Company, F. Hoffmann-La Roche, Ltd. (Genentech, Inc.), Pfizer, Inc., Johnson & Johnson (Janssen Global Services, LLC), Merck KGAA, and Novartis AG.

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the global cancer immunotherapy market size along with the current trends and future estimations to elucidate the imminent investment pockets
  • It offers market analysis from 2021 to 2030, which is expected to enable stakeholders to capitalize on the prevailing opportunities in the cancer immunotherapy market
  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global cancer immunotherapy market growth

Key Market Segments

By Technology Type

  • Monoclonal Antibodies
  • Cytokines & Immunomodulators
  • Others

By Application

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head & Neck Cancer
  • Others

By End user

  • Hospitals
  • Cancer Research Centers
  • Clinics

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East
    • Africa

List of key players profiled in the report

  • Amgen, Inc.
  • Astrazeneca, PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lily And Company
  • F. Hoffmann-La Roche, Ltd. (Genentech, Inc.)
  • Pfizer, Inc. 
  • Johnson & Johnson (Janssen Global Services, LLC)
  • Merck KGAA
  • Novartis AG
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in prevalence of cancer diseases
3.5.1.2.Rise in geriatric population
3.5.1.3.Growth in awareness among consumers regarding cancer immunotherapy
3.5.1.4.Increase in expenditure for the healthcare sector

3.5.2.Restraints

3.5.2.1.Risk of allergic reaction and limitations of the cancer immunotherapy treatment
3.5.2.2.Stringent government regulations

3.5.3.Opportunity

3.5.3.1.Increasing research and development in cancer immunotherapy
3.5.4.Impact analysis

3.6.Impact analysis of COVID-19 on the cancer immunotherapy market

CHAPTER 4:CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Monoclonal antibodies

4.2.1.Market size and forecast, by region
4.2.2.Market analysis, by country

4.3.Cytokines & Immunomodulators

4.3.1.Market size and forecast, by region
4.3.2.Market analysis, by country

4.4.Others

4.4.1.Market size and forecast, by region
4.4.2.Market analysis, by country

CHAPTER 5:CANCER IMMUNOTHERAPY MARKET, BY APPLICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Lung Cancer

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Breast Cancer

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Colorectal Cancer

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

5.5.Melanoma

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

5.6.Prostate Cancer

5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country

5.7.Head & Neck Cancer

5.7.1.Market size and forecast, by region
5.7.2.Market analysis, by country

5.8.Others

5.8.1.Market size and forecast, by region
5.8.2.Market analysis, by country

CHAPTER 6:CANCER IMMUNOTHERAPY MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospitals

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Cancer Research Centers

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Clinics

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

CHAPTER 7:CANCER IMMUNOTHERAPY MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.North America market size and forecast, by technologies type
7.2.2.North America market size and forecast, by application
7.2.3.North America market size and forecast, by end user
7.2.4.North America market size and forecast, by country

7.2.5.U.S.

7.2.5.1.U.S. market size and forecast, by technologies type
7.2.5.2.U.S. market size and forecast, by application
7.2.5.3.U.S. market size and forecast, by end user

7.2.6.Canada

7.2.6.1.Canada market size and forecast, by technologies type
7.2.6.2.Canada market size and forecast, by application
7.2.6.3.Canada market size and forecast, by end user

7.2.7.Mexico

7.2.7.1.Mexico market size and forecast, by technologies type
7.2.7.2.Mexico market size and forecast, by application
7.2.7.3.Mexico market size and forecast, by end user

7.3.Europe

7.3.1.Europe market size and forecast, by technologies type
7.3.2.Europe market size and forecast, by application
7.3.3.Europe market size and forecast, by end user
7.3.4.Europe market size and forecast, by country

7.3.5.Germany

7.3.5.1.Germany market size and forecast, by technologies type
7.3.5.2.Germany market size and forecast, by application
7.3.5.3.Germany market size and forecast, by end user

7.3.6.France

7.3.6.1.France market size and forecast, by technologies type
7.3.6.2.France market size and forecast, by application
7.3.6.3.France market size and forecast, by end user

7.3.7.UK

7.3.7.1.UK market size and forecast, by technologies type
7.3.7.2.UK market size and forecast, by application
7.3.7.3.UK market size and forecast, by end user

7.3.8.Italy

7.3.8.1.Italy market size and forecast, by technologies type
7.3.8.2.Italy market size and forecast, by application
7.3.8.3.Italy market size and forecast, by end user

7.3.9.Spain

7.3.9.1.Spain market size and forecast, by technologies type
7.3.9.2.Spain market size and forecast, by application
7.3.9.3.Spain market size and forecast, by end user

7.3.10.Rest of Europe

7.3.10.1.Rest of Europe market size and forecast, by technologies type
7.3.10.2.Rest of Europe market size and forecast, by application
7.3.10.3.Rest of Europe market size and forecast, by end user

7.4.Asia-Pacific

7.4.1.Asia-Pacific market size and forecast, by technologies type
7.4.2.Asia-Pacific market size and forecast, by application
7.4.3.Asia-Pacific market size and forecast, by end user
7.4.4.Asia-Pacific market size and forecast, by country

7.4.5.Japan

7.4.5.1.Japan market size and forecast, by technologies type
7.4.5.2.Japan market size and forecast, by application
7.4.5.3.Japan market size and forecast, by end user

7.4.6.China

7.4.6.1.China market size and forecast, by technologies type
7.4.6.2.China market size and forecast, by application
7.4.6.3.China market size and forecast, by end user

7.4.7.India

7.4.7.1.India market size and forecast, by technologies type
7.4.7.2.India market size and forecast, by application
7.4.7.3.India market size and forecast, by end user

7.4.8.Rest of Asia-Pacific

7.4.8.1.Rest of Asia-Pacific market size and forecast, by technologies type
7.4.8.2.Rest of Asia-Pacific market size and forecast, by application
7.4.8.3.Rest of Asia-Pacific market size and forecast, by end user

7.5.LAMEA

7.5.1.LAMEA market size and forecast, by technologies type
7.5.2.LAMEA market size and forecast, by application
7.5.3.LAMEA market size and forecast, by end user
7.5.4.LAMEA market size and forecast, by country

7.5.5.Latin America

7.5.5.1.Latin America market size and forecast, by technologies type
7.5.5.2.Latin America market size and forecast, by application
7.5.5.3.Latin America market size and forecast, by end user

7.5.6.Middle East

7.5.6.1.Middle East market size and forecast, by technologies type
7.5.6.2.Middle East market size and forecast, by application
7.5.6.3.Middle East market size and forecast, by end user

7.5.7.Africa

7.5.7.1.Africa market size and forecast, by technologies type
7.5.7.2.Africa market size and forecast, by application
7.5.7.3.Africa market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

8.1.AMGEN, INC.

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance

8.2.ASTRAZENECA, PLC.

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments

8.3.BAYER AG

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments

8.4.BRISTOL-MYERS SQUIBB COMPANY

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments

8.5.ELI LILY AND COMPANY

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments

8.6.F. HOFFMANN-LA ROCHE LTD (GENENTECH, INC.)

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments

8.7.JOHNSON & JOHNSON (Janssen Global Services, LLC)

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.MERCK KGAA

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.NOVARTIS AG

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.PFIZER INC.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.GLOBAL CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY TYPE, 2020–2030 ($MILLION)
TABLE 02.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR TEMPERATURE PATCH, BY REGION, 2020–2030 ($MILLION)
TABLE 03.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CYTOKINES AND IMMUNOMODULATORS, BY REGION, 2020–2030 ($MILLION)
TABLE 04.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR OTHERS, BY REGION, 2020–2030 ($MILLION)
TABLE 05.GLOBAL CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 06.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HEALTHCARE, BY REGION, 2020–2030 ($MILLION)
TABLE 07.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR BREAST CANCER, BY REGION, 2020–2030 ($MILLION)
TABLE 08.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2030 ($MILLION)
TABLE 09.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR MELANOMA, BY REGION, 2020–2030 ($MILLION)
TABLE 10.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2020–2030 ($MILLION)
TABLE 11.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 2020–2030 ($MILLION)
TABLE 12.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR OTHERS, BY REGION, 2020–2030 ($MILLION)
TABLE 13.GLOBAL CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 14.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HOSPITALS, BY REGION, 2020–2030 ($MILLION)
TABLE 15.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CANCER RESEARCH CENTERS, BY REGION, 2020–2030 ($MILLION)
TABLE 16.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CLINICS, BY REGION, 2020–2030 ($MILLION)
TABLE 17.CANCER IMMUNOTHERAPY MARKET, BY REGION, 2020–2030, ($MILLION)
TABLE 18.NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 19.NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 20.NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY END USE, 2020–2030, ($MILLION)
TABLE 21.NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 2020–2030, ($MILLION)
TABLE 22.U.S. CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 23.U.S. CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 24.U.S. CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 25.CANADA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 26.CANADA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 27.CANADA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 28.MEXICO CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 29.MEXICO CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 30.MEXICO CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 31.EUROPE CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 32.EUROPE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 33.EUROPE CANCER IMMUNOTHERAPY MARKET, BY END USE, 2020–2030, ($MILLION)
TABLE 34.EUROPE CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 2020–2030, ($MILLION)
TABLE 35.GERMANY CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 36.GERMANY CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 37.GERMANY CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 38.FRANCE CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 39.FRANCE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 40.FRANCE CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 41.UK CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 42.UK CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 43.UK CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 44.ITALY CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 45.ITALY CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 46.ITALY CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 47.SPAIN CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 48.SPAIN CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 49.SPAIN CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 50.REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 51.REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 52.REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 53.ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 54.ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 55.ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY END USE, 2020–2030, ($MILLION)
TABLE 56.ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 2020–2030, ($MILLION)
TABLE 57.JAPAN CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 58.JAPAN CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 59.JAPAN CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 60.CHINA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 61.CHINA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 62.CHINA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 63.INDIA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 64.INDIA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 65.INDIA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 66.REST OF ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 67.REST OF ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 68.REST OF ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 69.LAMEA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 70.LAMEA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 71.LAMEA CANCER IMMUNOTHERAPY MARKET, BY END USE, 2020–2030, ($MILLION)
TABLE 72.LAMEA CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 2020–2030, ($MILLION)
TABLE 73.LATIN AMERICA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 74.LATIN AMERICA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 75.LATIN AMERICA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 76.MIDDLE EAST CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 77.MIDDLE EAST CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 78.MIDDLE EAST CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 79.AFRICA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020–2030, ($MILLION)
TABLE 80.AFRICA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020–2030, ($MILLION)
TABLE 81.AFRICA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 82.MEDTRONIC: COMPANY SNAPSHOT
TABLE 83.AMGEN: OPERATING SEGMENTS
TABLE 84.AMGEN: PRODUCT PORTFOLIO
TABLE 85.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 86.ASTRAZENECA INC.: OPERATING SEGMENTS
TABLE 87.ASTRAZENECA INC.: PRODUCT PORTFOLIO
TABLE 88.BAYER : COMPANY SNAPSHOT
TABLE 89.BAYER : OPERATING SEGMENT
TABLE 90.BAYER : PRODUCT PORTFOLIO
TABLE 91.BMS: COMPANY SNAPSHOT
TABLE 92.BMS: PRODUCT PORTFOLIO
TABLE 93.ELI LILLY: COMPANY SNAPSHOT
TABLE 94.LILLY: OPERATING SEGMENTS
TABLE 95.ELI LILLY: PRODUCT PORTFOLIO
TABLE 96.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97.ROCHE: COMPANY SNAPSHOT
TABLE 98.ROCHE : OPERATING SEGMENTS
TABLE 99.ROCHE : PRODUCT PORTFOLIO
TABLE 100.ROCHE : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 101.J&J: COMPANY SNAPSHOT
TABLE 102.J&J: OPERATING BUSINESS SEGMENTS
TABLE 103.J&J: PRODUCT PORTFOLIO
TABLE 104.J&J : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105.MERCK: COMPANY SNAPSHOT
TABLE 106.MERCK: OPERATING SEGMENTS
TABLE 107.MERCK: PRODUCT PORTFOLIO
TABLE 108.NOVARTIS: COMPANY SNAPSHOT
TABLE 109.NOVARTIS: OPERATING SEGMENT
TABLE 110.NOVARTIS : PRODUCT PORTFOLIO
TABLE 111.PFIZER: COMPANY SNAPSHOT
TABLE 112.PFIZER: OPERATING SEGMENT
TABLE 113.PFIZER: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.GLOBAL CANCER IMMUNOTHERAPY MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07.HIGH BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR TEMPERATURE PATCH, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CYTOKINES AND IMMUNOMODULATORS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR LUNG CANCER, BY COUNTRY,  2020 & 2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR BREAST CANCER, BY COUNTRY,  2020 & 2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR MELANOMA, BY COUNTRY, 2020 & 2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY,  2020 & 2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CANCER RESEARCH CENTERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CLINICS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 26.AMGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 28.AMGEN: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 29.ASTRAZENECA: NET SALES, 2018–2020 ($MILLION)
FIGURE 30.ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 31.ASTRAZENECA: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 32.BAYER : NET SALES, 2018–2020 ($MILLION)
FIGURE 33.BAYER: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 34.BAYER: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 35.BMS: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.BMS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 37.ELI LILLY: NET SALES, 2018–2020 ($MILLION)
FIGURE 38.ELI LILLY: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 39.ELI LILLY: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 40.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.ROCHE: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 42.ROCHE: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 43.J&J: NET SALES, 2018–2020 ($MILLION)
FIGURE 44.J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 45.J&J: REVENUE SHARE BY REGION, 2020(%)
FIGURE 46.MERCK: NET SALES, 2018-2020 ($MILLION)
FIGURE 47.MERCK: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 48.MERCK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 49.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 50.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 51.NOVARTIS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 52.PFIZER: NET SALES, 2018–2020 ($MILLION)
FIGURE 53.PFIZER: REVENUE SHARE, BY REGION, 2020 (%)

 
 

Cancer immunotherapy, is commonly referred to as biologic therapy, helps in boosting the immunity of body to fight against cancer. In this type of therapy, antibodies and live viruses are introduced in the body that delay the growth of the cancer cells. 

Surge in incidence of cancer globally, increase in healthcare expenditure, and rise in geriatric population who are susceptible to suffer from cancer are anticipated to propel the growth of the global cancer immunotherapy market. Surge in awareness programs regarding the need for cancer immunotherapy is expected to help the market gain traction during the forecast period. Rise in the incidences of cancer is anticipated to propel the growth of the industry during the forecast period. However, factor such as stringent regulations related to cancer immunotherapy is expected to inhibit the growth of the cancer immunotherapy market. 

North America is expected to remain dominant during the forecast period, owing to increase in demand for cancer immunotherapy, rise in incidences of chronic orthopedic conditions, and presence of major key players along with R&D centers. Moreover, Asia-Pacific and LAMEA are expected to offer significant opportunities to key players during the forecast period, owing to increase in number of hospitals equipped with advanced medical facilities along with increase in utilization of cancer immunotherapy.
 

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. Cancer immunotherapy is a method of cancer treatment that helps in boosting immune system in fighting cancer.

A. Cancer immunotherapy is used for the treatment of cancer with the help of various technologies such as monoclonal antibodies and others and hence in destruction of the tumor cells from the body using immune system response.

A. The total value of cancer immunotherapy market was $85,603.5 million in 2020.

A. The forecast period in the report is from 2021-2030.

A. The market value of opthalmic devices market in 2030 was $3,09,667.5 million.

A. The base year calculated in the report is 2020.

A. Increased demand for the cancer immunotherapy and rise in incidences of cancer will drive the market over the near future according to the KOLs.

A. The market has drawn the interest of the healthcare industry, owing to increasing prevalence of cancer diseases, rise in technological advancements in cancer immunotherapy, and growing awareness among consumers regarding cancer immunotherapy

A. By technology type, themonoclonal antibodies segment holds the maximum market share.

A. The market in Asia-Pacific is expected to register lucrative CAGR of 11.00% over the forecast period owing to presence of large population base, increase in awareness regarding cancer immunotherapy, and rise in disposable income

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Cancer Immunotherapy Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers